UBS Group AG Cuts Holdings in Immunome, Inc. $IMNM

UBS Group AG reduced its position in Immunome, Inc. (NASDAQ:IMNM) by 47.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 307,194 shares of the company’s stock after selling 276,748 shares during the quarter. UBS Group AG owned about 0.33% of Immunome worth $6,599,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in IMNM. Assetmark Inc. purchased a new position in shares of Immunome in the 3rd quarter worth $39,000. BNP Paribas Financial Markets raised its position in shares of Immunome by 81.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock worth $60,000 after buying an additional 2,909 shares during the period. Tower Research Capital LLC TRC raised its position in shares of Immunome by 121.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock worth $65,000 after buying an additional 3,802 shares during the period. BIT Capital GmbH purchased a new position in shares of Immunome in the 3rd quarter worth $69,000. Finally, Russell Investments Group Ltd. acquired a new stake in Immunome in the 3rd quarter valued at $76,000. 44.58% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a report on Tuesday, April 21st. Leerink Partners lowered their price target on Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a report on Friday. Wall Street Zen upgraded Immunome from a “sell” rating to a “hold” rating in a report on Saturday. HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Immunome in a report on Wednesday, May 13th. Finally, Craig Hallum increased their price target on Immunome from $33.00 to $36.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $32.82.

Insider Transactions at Immunome

In other news, Director Jean Jacques Bienaime purchased 5,000 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The stock was acquired at an average cost of $20.70 per share, for a total transaction of $103,500.00. Following the completion of the purchase, the director owned 43,415 shares of the company’s stock, valued at approximately $898,690.50. This trade represents a 13.02% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Max Rosett sold 65,000 shares of Immunome stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $21.92, for a total value of $1,424,800.00. Following the completion of the transaction, the chief financial officer owned 54,037 shares of the company’s stock, valued at $1,184,491.04. This trade represents a 54.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 139,438 shares of company stock valued at $2,964,664 over the last ninety days. 7.21% of the stock is currently owned by company insiders.

Immunome Price Performance

Shares of Immunome stock opened at $19.66 on Wednesday. The company has a market capitalization of $2.23 billion, a PE ratio of -8.26 and a beta of 2.11. Immunome, Inc. has a 1-year low of $7.83 and a 1-year high of $27.65. The business has a 50-day moving average of $21.91 and a 200-day moving average of $21.27.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.48) EPS for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.12. On average, equities analysts expect that Immunome, Inc. will post -2.26 earnings per share for the current fiscal year.

Immunome Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.